These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 26921288

  • 1. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
    Caers J, Fernández de Larrea C, Leleu X, Heusschen R, Zojer N, Decaux O, Kastritis E, Minnema M, Jurczyszyn A, Beguin Y, Wäsch R, Palumbo A, Dimopoulos M, Mateos MV, Ludwig H, Engelhardt M.
    Oncologist; 2016 Mar; 21(3):333-42. PubMed ID: 26921288
    [Abstract] [Full Text] [Related]

  • 2. [Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma].
    Jurczyszyn A, Olszewska-Szopa M, Skotnicki AB.
    Przegl Lek; 2015 Mar; 72(11):642-8. PubMed ID: 27012123
    [Abstract] [Full Text] [Related]

  • 3. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
    Sundararajan S, Kumar A, Korde N, Agarwal A.
    Curr Hematol Malig Rep; 2016 Apr; 11(2):102-10. PubMed ID: 26894382
    [Abstract] [Full Text] [Related]

  • 4. New approaches to smoldering myeloma.
    Mateos MV, San Miguel JF.
    Curr Hematol Malig Rep; 2013 Dec; 8(4):270-6. PubMed ID: 23975678
    [Abstract] [Full Text] [Related]

  • 5. Advances in the management of asymptomatic myeloma.
    Mateos MV.
    Curr Opin Oncol; 2014 Nov; 26(6):670-6. PubMed ID: 25210868
    [Abstract] [Full Text] [Related]

  • 6. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
    Mateos MV, Landgren O.
    Cancer Treat Res; 2016 Nov; 169():3-12. PubMed ID: 27696254
    [Abstract] [Full Text] [Related]

  • 7. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW, Mutis T, Poddighe PJ, Lokhorst HM, Zweegman S.
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.
    Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, López Corral L, Rosiñol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, López J, Olavarría E, Quintana N, García JL, Bladé J, Lahuerta JJ, San Miguel JF.
    N Engl J Med; 2013 Aug 01; 369(5):438-47. PubMed ID: 23902483
    [Abstract] [Full Text] [Related]

  • 10. Smoldering Multiple Myeloma: To Treat or Not to Treat.
    Kapoor P, Rajkumar SV.
    Cancer J; 2019 Aug 01; 25(1):65-71. PubMed ID: 30694862
    [Abstract] [Full Text] [Related]

  • 11. Smoldering multiple myeloma.
    Gao M, Yang G, Kong Y, Wu X, Shi J.
    Biomed Res Int; 2015 Aug 01; 2015():623254. PubMed ID: 26000300
    [Abstract] [Full Text] [Related]

  • 12. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
    Golombick T, Diamond TH, Manoharan A, Ramakrishna R.
    Integr Cancer Ther; 2016 Jun 01; 15(2):183-9. PubMed ID: 27154182
    [Abstract] [Full Text] [Related]

  • 13. [Smoldering multiple myeloma].
    Fouquet G, Guidez S, Herbaux C, Demarquette H, Leleu X.
    Rev Med Interne; 2014 Apr 01; 35(4):243-9. PubMed ID: 24050785
    [Abstract] [Full Text] [Related]

  • 14. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).
    Mateos MV, Kumar S, Dimopoulos MA, González-Calle V, Kastritis E, Hajek R, De Larrea CF, Morgan GJ, Merlini G, Goldschmidt H, Geraldes C, Gozzetti A, Kyriakou C, Garderet L, Hansson M, Zamagni E, Fantl D, Leleu X, Kim BS, Esteves G, Ludwig H, Usmani S, Min CK, Qi M, Ukropec J, Weiss BM, Rajkumar SV, Durie BGM, San-Miguel J.
    Blood Cancer J; 2020 Oct 16; 10(10):102. PubMed ID: 33067414
    [Abstract] [Full Text] [Related]

  • 15. Smoldering multiple myeloma.
    Rajkumar SV, Landgren O, Mateos MV.
    Blood; 2015 May 14; 125(20):3069-75. PubMed ID: 25838344
    [Abstract] [Full Text] [Related]

  • 16. Progress in the Management of Smoldering Multiple Myeloma.
    Schmidt TM, Callander NS.
    Curr Hematol Malig Rep; 2021 Apr 14; 16(2):172-182. PubMed ID: 33983517
    [Abstract] [Full Text] [Related]

  • 17. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
    González-Calle V, Mateos MV.
    Eur J Intern Med; 2018 Dec 14; 58():57-63. PubMed ID: 29907380
    [Abstract] [Full Text] [Related]

  • 18. Smoldering multiple myeloma: when to observe and when to treat?
    Mateos MV, San Miguel JF.
    Am Soc Clin Oncol Educ Book; 2015 Dec 14; ():e484-92. PubMed ID: 25993213
    [Abstract] [Full Text] [Related]

  • 19. Smoldering multiple myeloma: to treat or not to treat.
    Gentile M, Offidani M, Vigna E, Corvatta L, Recchia AG, Morabito L, Martino M, Morabito F, Gentili S.
    Expert Opin Pharmacother; 2015 Apr 14; 16(6):785-90. PubMed ID: 25659943
    [Abstract] [Full Text] [Related]

  • 20. Smoldering, asymptomatic stage 1, and indolent myeloma.
    Greipp PR.
    Curr Treat Options Oncol; 2000 Jun 14; 1(2):119-26. PubMed ID: 12057049
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.